Back to the main directory
Press Release
- First Quantum Provides Update on Cobre Panamá by GlobeNewsWire
- Digi Power X Establishes US$100 Million at-the-Market Equity Program to Accelerate Growth by GlobeNewsWire
- New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 by GlobeNewsWire
- WithSecure on saattanut päätökseen kyberturvakonsultoinnin liiketoiminnan myynnin Neqstille by GlobeNewsWire
- Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde® by GlobeNewsWire
- Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer by GlobeNewsWire
- Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing by GlobeNewsWire
- Robex annonce la finalisation de son introduction en bourse by GlobeNewsWire
- Li Auto Inc. May 2025 Delivery Update by GlobeNewsWire
- NIO Inc. Provides May 2025 Delivery Update by GlobeNewsWire
- Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting by GlobeNewsWire
- Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025 by GlobeNewsWire
- Transgene et NEC présentent une survie sans récidive durable, accompagnée d’une réponse cellulaire T persistante à 24 mois avec le vaccin thérapeutique individualisé TG4050 by GlobeNewsWire
- Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML by GlobeNewsWire
- HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting by GlobeNewsWire
- Ipsen S.A. - Initiation of the share buy-back program by GlobeNewsWire
- WISeKey’s WISe.ART 3.0, One of the World’s First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN’s MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30 by GlobeNewsWire
- AVTL successfully completed IPO by GlobeNewsWire
- DNO Contemplates Hybrid Bond Issue by GlobeNewsWire
- Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] by GlobeNewsWire
- Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce by GlobeNewsWire
- Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce by GlobeNewsWire
- Atos Group receives confirmatory offer from the French State to acquire part of its former Advanced Computing business by GlobeNewsWire
- BW Offshore: Dividend information by GlobeNewsWire
- ASi Ekspress Grupp dividendimakse ex-päev by GlobeNewsWire